Press release
Seborrhea Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics
Seborrhea Pipeline Analysis
DelveInsight reports that over three key companies are actively engaged in the development of more than three treatment therapies for Seborrhea.
Seborrhea Overview:
Seborrhea is a long-term inflammatory skin disorder marked by the accumulation of oily, flaky scales. It often appears as yellowish, crusty, and itchy patches, particularly on the scalp-commonly referred to as dandruff. Other commonly affected areas include the face, ears, eyebrows, eyelids, belly button, and genital region. The condition can be classified as either primary, which is inherited, or secondary, which is more prevalent and often has no clearly identifiable cause. Factors such as hormonal changes, stress, and the presence of a yeast-like fungus are believed to contribute to its onset. Seborrhea can impact people across all age groups-from infants to older adults-and is more frequently observed in males and individuals with oily skin.
Request for a detailed insights report on Seborrhea pipeline insights @ https://www.delveinsight.com/report-store/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Seborrhea Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Seborrhea Therapeutics Market.
Key Takeaways from the Seborrhea Pipeline Report
*
DelveInsight's Seborrhea pipeline report highlights an active and evolving landscape, with more than three companies working on the development of therapies for Seborrhea. Leading companies such as Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics, and others are investigating new drug candidates aimed at enhancing treatment options for the condition.
*
Among the promising therapies in development is ARQ154 (Topical Roflumilast Foam), along with others in various stages of clinical progress.
*
In a significant advancement, the U.S. FDA approved Zoryve (roflumilast) topical foam, 0.3%, in December 2023 for the treatment of seborrheic dermatitis in patients aged 9 and above. This marks the first approval of a therapy with a new mechanism of action for this condition in over 20 years.
Seborrhea Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Seborrhea Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Seborrhea treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Seborrhea market.
Download our free sample page report on Seborrhea pipeline insights [https://www.delveinsight.com/sample-request/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Seborrhea Emerging Drugs
*
ARQ154 (Topical Roflumilast Foam): Arcutis Biotherapeutics, Inc.
Since 2011, the U.S. Food and Drug Administration (FDA) has approved roflumilast for systemic use to help reduce the risk of exacerbations in chronic obstructive pulmonary disease (COPD). Arcutis Biotherapeutics Inc. recently reported positive topline results from its Phase 2 clinical trial evaluating ARQ-154, a topical foam formulation of roflumilast, as a potential treatment for seborrheic dermatitis. This foam-based version, ARQ-154, is a highly potent and selective PDE4 inhibitor.
Seborrhea Companies
Multiple leading companies are actively working on therapies for seborrhea. Among them, Arcutis Biotherapeutics Inc. has a drug candidate that is the furthest along in development, currently in Phase II clinical trials.
DelveInsight's report covers around 3+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Seborrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Seborrhea Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Seborrhea Therapies and Key Companies: Seborrhea Clinical Trials and advancements [https://www.delveinsight.com/report-store/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Seborrhea Pipeline Therapeutic Assessment
- Seborrhea Assessment by Product Type
- Seborrhea By Stage
- Seborrhea Assessment by Route of Administration
- Seborrhea Assessment by Molecule Type
Download Seborrhea Sample report to know in detail about the Seborrhea treatment market @ Seborrhea Therapeutic Assessment [https://www.delveinsight.com/sample-request/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Seborrhea Current Treatment Patterns
4. Seborrhea - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Seborrhea Late-Stage Products (Phase-III)
7. Seborrhea Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Seborrhea Discontinued Products
13. Seborrhea Product Profiles
14. Seborrhea Key Companies
15. Seborrhea Key Products
16. Dormant and Discontinued Products
17. Seborrhea Unmet Needs
18. Seborrhea Future Perspectives
19. Seborrhea Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Seborrhea Pipeline Reports Offerings [https://www.delveinsight.com/report-store/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=seborrhea-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-arcutis-biotherapeutics-cutanea-life-sciences-inc-vyome-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Seborrhea Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics here
News-ID: 4136017 • Views: …
More Releases from ABNewswire
Total Joy Homecare Responds to Surging Demand for Senior Health Care Services in …
Total Joy Homecare expands services to meet growing Houston demand for in-home senior care, offering non-medical support that helps families maintain independence and dignity at home.
Houston's rapidly aging demographic has prompted local care provider Total Joy Homecare to expand its comprehensive support services, addressing the critical need for quality senior health care services [https://maps.app.goo.gl/hUcW1N7qWy5EdHJs5] throughout the Greater Houston area. The company's response comes as families increasingly seek reliable alternatives to…
Texas Company Introduces On-Site Carrier Repair Services to Reduce Fleet Downtim …
Texas Reefer Solutions introduces mobile carrier repair services in Dallas, revolutionizing how transportation fleets handle refrigeration breakdowns by providing on-site professional repairs, eliminating route deviations, and reducing cargo-threatening delays.
The transportation industry faces a significant challenge when refrigerated trucks require repairs, often forcing drivers to deviate from critical routes and schedules. Texas Reefer Solutions has emerged as a game-changing solution, introducing mobile carrier repair services [https://maps.app.goo.gl/P6nfg5WF7sckR7aZ8] that bring professional technicians directly…
Family Therapy in Birmingham: How the Right Therapist Can Transform Relationship …
Family therapy in Birmingham helps families improve communication, resolve conflict, and build stronger bonds. With the support of a qualified therapist near you, therapy creates a safe space to share, heal, and reconnect. Whether you're searching for therapy near me or counselling for your family, Phinity Therapy offers guidance for lasting change.
Families are the foundation of our lives. They provide love, support, and connection, but they can also be the…
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Seborrhea
Seborrhea Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessme …
Seborrhea Pipeline constitutes 3+ key companies continuously working towards developing 3+ Seborrhea treatment therapies, analyzes DelveInsight.
Seborrhea Overview:
Seborrhea is a chronic inflammatory skin condition characterized by the buildup of greasy scales. It may present as yellow, crusted, and itchy plaques, often affecting the scalp, where it is commonly known as dandruff. Other areas prone to seborrhea include the face, ears, eyebrows, eyelids, umbilicus, and genital region. The condition can be either…
Seborrhea Drugs Market 2022 Industry Size Forecast by Share, Revenue, Growth and …
The Seborrhea Drugs Market report provides a comprehensive analysis of the global market, taking into consideration its history, current scenario, and future development trends. It also examines market aspects such as trends, share, forecast, outlook, production, and future growth potential. The report also details various new trends and technologies that are being adopted by the various players in the Seborrhea Drugs Market to propel their business in a positive direction.…
Seborrhea Drugs Market is foreseen to grow at CAGR of +11% by 2030 |Aclaris Ther …
" There is no one-size-fits-all answer to this question, as the treatment for seborrhea will vary depending on the underlying cause of the condition. However, some common medications used to treat seborrhea include topical steroids, antifungal medications, and medicated shampoos.
Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @: https://a2zmarketresearch.com/sample-request/932277
The global Seborrhea Drugs Market is expected to grow at a significant CAGR of +11% during the…
EVE Medical device for Face | Weero
WEERO is a global manufacturer that offers the most cutting-edge and modern aesthetic medical and beauty device. All products are made in accordance with the ISO 13485 quality system.
Weero EVE Ace of Face
For the convenience of consumers, EVE combines three distinct technologies-EMS, Microcurrent, and Hydra-dermabrasion into a single device.
EVE was created emphasizing user ease by enabling quick and easy processes and creating tips
for various purposes and professional duties.
Features and Benefits…
BEST Synergy Programs of Microcurrent / EMS / Hydra-dermabrasion | Weero
WEERO is a global manufacturer providing the most advanced and newest aesthetic medical devices and beauty devices to the world All devices are manufactured under the ISO 13485 quality system.
WEERO EVE
EVE combines three unique technologies of EMS, Microcurrent, and Hydra-dermabrasion in one device to conveniently provide users with a variety of treatment programs.
EVE has been developed with user-centric perspective, focusing on maximizing user convenience by enabling quick and smooth procedures…
Global Seborrhea Drugs Market 2019 | Major Key Players: Aclaris Therapeutics Inc …
WiseGuyReports.Com adds “Seborrhea Drugs Market - 2019” research report to its database
Description :
The global Seborrhea Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Seborrhea Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Seborrhea Drugs market size…
